The European Commission has introduced the European Biotech Act, an ambitious initiative designed to strengthen Europe’s biotechnology and biomanufacturing ecosystem. More than a regulatory update, the proposal signals a strategic effort to make the European Union more competitive by reducing barriers to innovation, accelerating pathways to market, and creating an environment where scientific advances can scale more efficiently.
For years, Europe has faced a recurring challenge: while it produces world-class scientific research, innovators often encounter lengthy procedures, complex regulatory requirements, and fragmented national systems. These obstacles have frequently pushed startups and investments to grow elsewhere.
The European Biotech Act aims to address this gap.
While healthcare remains a major focus of the initiative, the proposal could also have important consequences for the food sector. In particular, several measures may significantly affect how food innovation is assessed and how the European Food Safety Authority (EFSA) supports companies bringing new technologies to market.
Below are some of the key questions surrounding this proposal and what it could mean for the future of food innovation.
What is the European Biotech Act?
The European Biotech Act is a strategic initiative intended to strengthen Europe’s biotechnology sector and support the transition from scientific discovery to industrial and commercial development.
The proposal seeks to address structural barriers that currently slow innovation, including:
- Long authorization timelines
- Fragmented national procedures
- Difficulties in scaling innovation
- Limited access to funding pathways
Its broader objective is to create a more predictable and innovation-friendly framework capable of supporting biotech growth across the EU.
What are the main objectives of the European Biotech Act?
The proposal introduces several measures intended to simplify and accelerate innovation processes:
- Strategic Projects may benefit from accelerated authorization procedures and improved access to capital.
- Artificial Intelligence integration could support different stages of biotech development and regulatory assessment.
- Regulatory simplification measures aim to reduce administrative complexity and create greater harmonization across Member States.
- Regulatory sandboxes could provide controlled environments where innovative technologies can be tested before broader implementation.
Together, these measures suggest a shift toward a more proactive and innovation-oriented regulatory approach.
Why does the Biotech Act matter for the food industry?
Although biotechnology is often associated with healthcare applications, the food industry could be among the most affected industries.
Areas such as precision fermentation, alternative proteins, biotechnology-derived ingredients, and advanced food technologies increasingly challenge traditional regulatory pathways. As innovation develops more rapidly than regulatory systems can adapt, companies frequently face long and complex approval procedures.
The proposed framework seeks to improve this process by supporting earlier engagement between innovators and regulators while maintaining Europe’s high standards for consumer protection and scientific assessment.
For food companies, particularly SMEs and startups, this could create a more efficient path from innovation to market.
How could the Act change EFSA’s role?
One of the most significant proposals concerns EFSA’s responsibilities.
Currently, EFSA’s pre-submission advice is largely focused on administrative guidance. Under the Biotech Act, this support could be expanded to include scientific advice on study design and testing strategies.
EFSA estimates approximately 200 requests per year for this expanded scientific support across areas such as:
- Novel foods
- Food additives
- GMOs
- Emerging biotech applications
The objective is to help applicants submit stronger dossiers from the beginning and reduce the “stop-the-clock” delays that often prolong risk assessments.
For companies navigating complex regulatory pathways, this could represent a meaningful change.
Could EFSA undergo structural changes as well?
Yes. The proposal also includes internal changes intended to improve coordination and consistency.
Under the new framework, EFSA staff members would chair Scientific Panels and the Scientific Committee. While these representatives would not have voting rights, their role would support greater alignment and efficiency across scientific evaluations. Although procedural in nature, these changes could influence how scientific assessments are coordinated in the future.
How would these additional responsibilities be funded?
The Commission recognizes that expanding EFSA’s responsibilities would require additional operational support.
To address this, the proposal includes:
- Additional staffing
- Increased financial resources
- Expanded administrative capacity
It also introduces the possibility of applicant fees to partially or fully support certain specialized services. This may eventually influence both timelines and regulatory costs for future applicants.
What are regulatory sandboxes and why do they matter?
Among the most innovative aspects of the proposal is the introduction of regulatory sandboxes.
These controlled environments would allow Member States to test innovative technologies under adapted regulatory conditions while maintaining safeguards for health and environmental protection. For example, alternative approaches such as digital labeling solutions could be evaluated before wider implementation.
However, Novel Foods are specifically excluded from these mechanisms due to ethical and cultural considerations.
Even with this limitation, the concept reflects a broader effort to create more flexible and innovation-oriented regulatory systems.
When could these changes take effect?
The proposed Regulation would enter into force 20 days after official publication, although implementation will occur gradually.
The first phase is expected to focus on strategic mapping of Europe’s biotech landscape and the designation of national contact points to support project promoters.
Some food-related reforms may apply relatively quickly, while others could be introduced progressively over six to nine months.
The Commission currently anticipates full transition and operational implementation during the 2028–2029 period, aligned with the next EU budget cycle.
For industry stakeholders, this means the discussion is no longer only about future possibilities—but about preparing for regulatory changes that may progressively reshape the European innovation landscape.
What could this mean for the future of food innovation?
The European Biotech Act has the potential to become more than a technical regulatory reform.
It may represent a broader evolution in how Europe approaches innovation, scientific assessment, and market access.
For food companies, understanding these developments early may be essential. Regulatory frameworks are evolving, and the organizations best prepared to anticipate change are often those best positioned to benefit from it.
At Chemsafe, we help companies stay ahead of regulatory change. From EFSA strategies and food compliance support to scientific and regulatory guidance, we help innovators navigate complexity and transform regulatory challenges into opportunities for growth. Contact us now to find out more!
